Royal Bank Of Canada upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a sector perform rating to an outperform rating in a research report report published on Monday. The brokerage currently has $83.00 price objective on the stock.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Several other equities analysts also recently issued reports on SRPT. Oppenheimer Holdings Inc. reiterated a buy rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday, July 17th. Piper Jaffray Cos. reiterated a sell rating and issued a $6.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, June 4th. Robert W. Baird reiterated an outperform rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Vetr downgraded Sarepta Therapeutics from a buy rating to a strong sell rating and set a $17.28 price objective for the company. in a research report on Wednesday, June 8th. Finally, Janney Montgomery Scott reiterated a hold rating on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $48.70.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Monday. The stock’s market capitalization is $2.92 billion. The stock’s 50 day moving average price is $30.01 and its 200 day moving average price is $21.91. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $61.60.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the company posted ($0.87) earnings per share. On average, analysts forecast that Sarepta Therapeutics will post ($4.17) EPS for the current year.

In related news, SVP David T. Howton sold 9,304 shares of the company’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $465,200.00. Following the sale, the senior vice president now owns 11,168 shares in the company, valued at $558,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.

A number of institutional investors have recently made changes to their positions in SRPT. BlackRock Fund Advisors increased its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the period. State Street Corp increased its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares during the period. Commonwealth Equity Services Inc acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $302,000. National Planning Corp increased its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the period. 72.09% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.